by Raynovich Rod | Dec 16, 2013 | 2024 Rayno Tools and Diagnostics Portfolio, Biopharmaceuticals
But A Lot of Green Today in Diagnostics and Tools The NASDAQ (4030)and the S&P (1787) are up about 0.7% but biotech stocks are lagging with the IBB ($216) up only 0.33%. Momentum in biopharmaceutical stocks has been easing since a late November move around the...
by Raynovich Rod | Nov 21, 2013 | 2024 Rayno Tools and Diagnostics Portfolio
Another Strong Day in Life Science Stocks Carl Icahn, activist investor takes a 13% stake in Hologic. Hologic (HOLX $22.82) was added to our portfolio on 4/9/13 but has been a laggard due to earnings misses. The stock is up 2.4% on a volume of 25M shares. Many stocks...
by Raynovich Rod | Nov 14, 2013 | 2024 Rayno Tools and Diagnostics Portfolio
Rayno Diagnostics and Tools Focus Stocks: 2013 Performance YTD A diversified life science portfolio must include clinical diagnostics and tools stocks because the synergies between therapy and diagnostics have never been stronger. Breakthroughs in molecular...
by Raynovich Rod | Aug 20, 2013 | 2024 Rayno Tools and Diagnostics Portfolio
Diagnostics Company Stocks Are Off Their 2013 Highs Life science tools and diagnostics stocks are near all time highs despite stretched valuations because of a strong secular biotech bull market and perceived synergy with biopharmaceuticals. Key themes are point of...
by Raynovich Rod | Aug 13, 2013 | Biopharmaceuticals
Market Can’t Stay Down in Quiet Trading After a couple of lackluster trading days the market perked up as economic news continues positive with retail sales up for the fourth consecutive month and many analysts believing Europe is coming out of recession. And...
by Raynovich Rod | Aug 7, 2013 | Clinical Diagnostics and Tools
The 2013 AACC (American Association for Clinical Chemistry) Meeting was attended by 650 exhibitors and over 17,000 professionals all looking to connect in the In Vitro Diagnostics (IVD) industry. For a complete up-to-date news and analysis of the industry check...
by Raynovich Rod | Jul 25, 2013 | 2024 Rayno Tools and Diagnostics Portfolio
Diagnostics and Tools Stocks Are At New Highs We will be attending the American Association of Clinical Chemistry Meeting in Houston next week. Our focus stocks are summarized below and as you can see they have already made huge moves this year.In the past we have...
by Raynovich Rod | Jun 20, 2013 | 2024 Rayno Biopharmaceuticals Portfolio, 2024 Rayno Tools and Diagnostics Portfolio
Rayno Diagnostics and Tools Portfolio Prices as of 5/29/13 Top 2013 Winners: ABAX, ALR, CSII, GHDX, ILMN, TMO, VRML Sector high was in mid-May Less volatile than biopharma but more dependent on earnings Five companies on focus list were acquired over 3 years...
by Raynovich Rod | Jun 13, 2013 | 2024 Rayno Tools and Diagnostics Portfolio, BIOgraph
6/14 Supreme Court Ruling on Genetic Tests Takes Down Myriad Stock (MYGN $30.50)-Off Another 3% but still up 13% YTD. The Supreme Court ruling opens up competition for Myriad’s breast cancer tests as well as other genetic disease markers.The immediate reaction...
by Raynovich Rod | May 29, 2013 | Clinical Diagnostics and Tools
Rayno Diagnostics and Tools Portfolio Rayno Life Science top picks were up 20 to 53% beating the NASDAQ and S&P. Five new stocks were added in 2013: BG Medicine (BGMD), Genomic Health (GHDX), Hologic (HOLX), Vermillion (VRML). One major trend is larger cap...